{"id":605,"slug":"what-conditions-can-stem-cell-therapy-treat","question":"What conditions can stem cell therapy treat?","intent":"informational","language":"en","url":"https://worldwiki.io/q/what-conditions-can-stem-cell-therapy-treat","entity":{"slug":"stem-cell-therapy","name":"Stem Cell Therapy","url":"https://worldwiki.io/entity/stem-cell-therapy"},"answer":{"short_answer":"Proven uses are mainly blood and immune system disorders. These are treated with hematopoietic stem cell transplantation, which has been used for more than 50 years, mostly for lymphomas, myeloma and leukemias. Stem cells are also used in some skin and cornea grafts. Regulators have approved a few other products for narrow indications, such as limbal stem cell deficiency in the EU and ALS or knee osteoarthritis in South Korea. Other uses remain experimental.","detailed_answer":"<p>In 2016, lymphoproliferative disorders made up 53.0% of HSCTs worldwide and leukemias 35.7%.<span class=\"ref\">[3]</span> The FDA states that regenerative products are not approved for conditions such as autism, Alzheimer's disease, Parkinson's disease or orthopedic conditions.<span class=\"ref\">[1]</span></p>","format":"paragraph","confidence":75,"verified_at":"2026-09-18 06:21:20","updated_at":"2026-09-18 15:21:20"},"sources":[{"id":96,"title":"Important Patient and Consumer Information About Regenerative Medicine Therapies","url":"https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies","publisher":"U.S. Food and Drug Administration","type":"government","accessed_at":"2026-09-18 18:00:38"},{"id":97,"title":"Approved Cellular and Gene Therapy Products","url":"https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products","publisher":"U.S. Food and Drug Administration","type":"government","accessed_at":"2026-09-18 18:00:38"},{"id":98,"title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors (Niederwieser D, et al., Haematologica 107(5):1045-1053)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9052915/","publisher":"Haematologica","type":"journal","accessed_at":"2026-09-19 18:01:25"},{"id":99,"title":"Stem Cell Resources for Patients","url":"https://www.isscr.org/patients","publisher":"International Society for Stem Cell Research (ISSCR)","type":"organization","accessed_at":"2026-09-19 18:01:26"},{"id":100,"title":"Graft-versus-host disease: MedlinePlus Medical Encyclopedia","url":"https://www.medlineplus.gov/ency/article/001309.htm","publisher":"U.S. National Library of Medicine (MedlinePlus)","type":"government","accessed_at":"2026-09-19 18:01:26"},{"id":101,"title":"Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World (Fernández-Garza LE, et al., Pharmaceuticals 16(9):1334)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10536665/","publisher":"Pharmaceuticals (MDPI)","type":"journal","accessed_at":"2026-09-19 18:01:27"},{"id":102,"title":"Alofisel: EPAR","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel","publisher":"European Medicines Agency","type":"government","accessed_at":"2026-09-19 18:01:28"},{"id":103,"title":"FDA Approves Remestemcel-L-Rknd for Steroid-Refractory Acute Graft-Versus-Host Disease in Pediatric Patients","url":"https://www.ons.org/publications-research/voice/news-views/12-2024/fda-approves-remestemcel-l-rknd-steroid-refractory","publisher":"Oncology Nursing Society","type":"organization","accessed_at":"2026-09-19 18:01:29"},{"id":104,"title":"New legal category of 'advanced regenerative medicine treatment' in Korea's amended regenerative medicine law: comparative lessons from Japan (Yoon, Lee, Kim)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13083794/","publisher":"Stem Cell Reports","type":"journal","accessed_at":"2026-09-19 18:01:29"},{"id":105,"title":"Unproven stem cell therapy for macular degeneration (Ansari ZA, Kuriyan AE, Albini TA)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5710873/","publisher":"Oncotarget","type":"journal","accessed_at":"2026-09-19 18:01:30"}],"published_at":"2026-09-18 06:21:20"}